/ELEV

ELEV Stock - Elevation Oncology, Inc.

Q: What is the analyst price target for ELEV?

Analyst price target information is not currently available for ELEV.

Q: What is ELEV's market cap?

Market capitalization information is not currently available for ELEV.

Healthcare|Biotechnology|NASDAQ

$0.36-2.12%

$0.01 (-2.12%) • Jul 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+2365.8%upside

Target: $9.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ELEV

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.50

52W High$3.09

52W Low$0.22

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-24,000	$-39,000	$-27,000	$-18,000	$-15,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-44,703,000	$-45,445,000	$-94,549,000	$-32,046,000	$-17,276,000
Net Income	$-44,485,000	$-45,704,000	$-95,080,000	$-32,039,000	$-17,265,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.78	$-1.34	$-4.09	$-1.38	$-0.73

Company Overview

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

60%

Hold / Neutral

40%

Sell / Underperform

Analyst Consensus🟡 Mixed

3 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 1297.3% Upside

Now

Low

Average

$10

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 24th 2025	Stephens	Downgrade	Equal Weight	$1← $5
March 21st 2025	Leerink Partners	Downgrade	Market Perform	$1
March 21st 2025	Citizens JMP	Downgrade	Market Perform	-
March 21st 2025	Piper Sandler	Downgrade	Neutral	$0.7
January 3rd 2025	William Blair	Initiation	Outperform	-
May 31st 2024	Piper Sandler	Initiation	Overweight	$10
May 14th 2024	Stephens	Initiation	Overweight	$8
March 1st 2024	JMP Securities	Initiation	Mkt Outperform	$7
May 30th 2023	SVB Securities	Upgrade	Outperform	$8← $5

Earnings History & Surprises

ELEV

Beat Rate

41%

Last 17 quarters

Avg Surprise

-10.6%

EPS vs Estimate

Beats / Misses

7/10

Last 12 quarters

Latest EPS

$-0.18

Q3 2025

EPS Surprise History

Q4 23

+26.5%

$-0.25vs$-0.34

Q1 24

+9.5%

$-0.19vs$-0.21

Q2 24

-9.5%

$-0.23vs$-0.21

Q3 24

+21.7%

$-0.18vs$-0.23

Q4 24

-10.0%

$-0.22vs$-0.20

Q1 25

+18.2%

$-0.18vs$-0.22

Q2 25

-20.0%

$-0.24vs$-0.20

Q3 25

+30.8%

$-0.18vs$-0.26

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 5, 2025	$-0.26	$-0.18	+30.8%	✓ BEAT
Q2 2025	May 15, 2025	$-0.20	$-0.24	-20.0%	✗ MISS
Q1 2025	Mar 6, 2025	$-0.22	$-0.18	+18.2%	✓ BEAT
Q4 2024	Nov 6, 2024	$-0.20	$-0.22	-10.0%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.23	$-0.18	+21.7%	✓ BEAT
Q2 2024	May 2, 2024	$-0.21	$-0.23	-9.5%	✗ MISS
Q1 2024	Mar 6, 2024	$-0.21	$-0.19	+9.5%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.34	$-0.25	+26.5%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.28	$-0.37	-32.1%	✗ MISS
Q2 2023	May 15, 2023	$-0.51	$-0.50	+2.0%	✓ BEAT
Q1 2023	Mar 9, 2023	$-0.67	$-0.82	-22.4%	✗ MISS
Q4 2022	Nov 3, 2022	$-1.12	$-1.67	-49.1%	✗ MISS
Q3 2022	Aug 4, 2022	$-0.80	$-0.86	-7.5%	✗ MISS
Q2 2022	May 5, 2022	$-0.51	$-0.74	-45.1%	✗ MISS
Q1 2022	Mar 3, 2022	$-0.59	$-0.41	+30.5%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.35	$-0.53	-51.4%	✗ MISS
Q3 2021	Aug 12, 2021	$-2.82	$-4.84	-71.6%	✗ MISS
Q2 2021	Jun 25, 2021	—	$-0.54	—	—
Q1 2021	Mar 31, 2021	—	$-0.22	—	—
Q3 2020	Sep 30, 2020	—	$-0.18	—	—

Frequently Asked Questions about ELEV

What is ELEV's current stock price?

Elevation Oncology, Inc. (ELEV) is currently trading at $0.36 per share. The stock has moved -2.12% today.

What is the analyst price target for ELEV?

The average analyst price target for ELEV is $9.00, based on 1 analyst.

What sector is Elevation Oncology, Inc. in?

Elevation Oncology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ELEV's market cap?

Elevation Oncology, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.

Does ELEV pay dividends?

No, Elevation Oncology, Inc. does not currently pay a dividend to shareholders.